

## S 3311

### American Made Pharmaceuticals Act of 2023

**Congress:** 118 (2023–2025, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Nov 15, 2023

**Current Status:** Committee on Banking, Housing, and Urban Affairs. Hearings held.

**Latest Action:** Committee on Banking, Housing, and Urban Affairs. Hearings held. (Jul 25, 2024)

**Official Text:** <https://www.congress.gov/bill/118th-congress/senate-bill/3311>

## Sponsor

**Name:** Sen. Smith, Tina [D-MN]

**Party:** Democratic • **State:** MN • **Chamber:** Senate

## Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cotton, Tom [R-AR]	R · AR		Nov 15, 2023
Sen. Bennet, Michael F. [D-CO]	D · CO		Dec 6, 2023

## Committee Activity

Committee	Chamber	Activity	Date
Banking, Housing, and Urban Affairs Committee	Senate	Hearings By (full committee)	Jul 25, 2024
Finance Committee	Senate	Referred To	Nov 15, 2023

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## American Made Pharmaceuticals Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

### **Actions Timeline**

---

- **Jul 25, 2024:** Committee on Banking, Housing, and Urban Affairs. Hearings held.
- **Nov 15, 2023:** Introduced in Senate
- **Nov 15, 2023:** Read twice and referred to the Committee on Finance.